Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
$39.26
-0.7%
$32.54
$23.42
$62.58
$2.27B0.73654,546 shs141,372 shs
Howard Hughes Holdings Inc. stock logo
HHH
Howard Hughes
$70.39
-1.0%
$69.00
$59.83
$87.77
$3.55B1.21376,328 shs97,405 shs
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
$2.65
+3.7%
$2.54
$1.05
$3.31
$567.78M0.972.93 million shs749,698 shs
Vericel Corporation stock logo
VCEL
Vericel
$40.26
-2.4%
$41.85
$37.39
$63.00
$2.03B1.32420,017 shs20,964 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
+1.18%+9.64%+14.55%+48.05%-9.11%
Howard Hughes Holdings Inc. stock logo
HHH
Howard Hughes
+1.48%+2.49%+0.58%+8.98%+7.00%
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
+0.39%+6.25%-2.30%+104.82%+12.83%
Vericel Corporation stock logo
VCEL
Vericel
-0.65%-1.33%-9.78%-0.05%-9.28%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
4.1047 of 5 stars
3.41.00.04.31.90.81.9
Howard Hughes Holdings Inc. stock logo
HHH
Howard Hughes
2.5487 of 5 stars
2.33.00.00.02.03.31.3
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
2.6965 of 5 stars
4.51.00.00.00.63.30.0
Vericel Corporation stock logo
VCEL
Vericel
2.9526 of 5 stars
3.51.00.00.03.30.81.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
2.71
Moderate Buy$58.6049.26% Upside
Howard Hughes Holdings Inc. stock logo
HHH
Howard Hughes
2.67
Moderate Buy$80.3314.13% Upside
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
3.00
Buy$8.17208.76% Upside
Vericel Corporation stock logo
VCEL
Vericel
3.00
Buy$61.1451.87% Upside

Current Analyst Ratings Breakdown

Latest TSHA, HHH, VCEL, and AGIO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/11/2025
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$8.00
7/1/2025
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
6/23/2025
Howard Hughes Holdings Inc. stock logo
HHH
Howard Hughes
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral$82.00 ➝ $76.00
6/16/2025
Vericel Corporation stock logo
VCEL
Vericel
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$67.00
6/10/2025
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
6/3/2025
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$9.00 ➝ $11.00
6/2/2025
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00 ➝ $8.00
5/29/2025
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
5/29/2025
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$5.00 ➝ $6.00
5/29/2025
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$7.00 ➝ $9.00
5/23/2025
Howard Hughes Holdings Inc. stock logo
HHH
Howard Hughes
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$105.00 ➝ $85.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
$37.04M61.39N/AN/A$27.02 per share1.45
Howard Hughes Holdings Inc. stock logo
HHH
Howard Hughes
$1.75B2.03$9.74 per share7.23$56.65 per share1.24
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
$8.33M68.16N/AN/A$0.35 per share7.56
Vericel Corporation stock logo
VCEL
Vericel
$238.54M8.50$0.30 per share132.80$5.92 per share6.80
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
$673.72M$11.243.49N/AN/A1,798.26%-2.75%-2.52%7/30/2025 (Estimated)
Howard Hughes Holdings Inc. stock logo
HHH
Howard Hughes
$200.55M$5.2113.5176.51N/A14.27%10.21%3.08%N/A
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
-$89.30M-$0.34N/AN/AN/A-1,201.08%-104.93%-50.09%8/11/2025 (Estimated)
Vericel Corporation stock logo
VCEL
Vericel
$10.36M$0.031,342.4591.50N/A1.25%1.09%0.73%7/30/2025 (Estimated)

Latest TSHA, HHH, VCEL, and AGIO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
-$1.74N/AN/AN/AN/AN/A
8/7/2025Q2 2025
Vericel Corporation stock logo
VCEL
Vericel
-$0.04N/AN/AN/A$64.61 millionN/A
5/15/2025Q1 2025
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
-$0.08-$0.08N/A-$0.08$1.48 million$2.30 million
5/8/2025Q1 2025
Vericel Corporation stock logo
VCEL
Vericel
-$0.09-$0.23-$0.14-$0.23$53.86 million$52.60 million
5/7/2025Q1 2025
Howard Hughes Holdings Inc. stock logo
HHH
Howard Hughes
$0.13$0.21+$0.08$0.21$187.43 million$199.33 million
5/1/2025Q1 2025
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
-$1.80-$1.55+$0.25-$1.55$9.86 million$8.73 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
N/AN/AN/AN/AN/A
Howard Hughes Holdings Inc. stock logo
HHH
Howard Hughes
N/AN/AN/AN/AN/A
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
N/AN/AN/AN/AN/A
Vericel Corporation stock logo
VCEL
Vericel
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
N/A
18.50
17.93
Howard Hughes Holdings Inc. stock logo
HHH
Howard Hughes
1.84
1.41
1.41
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
0.77
5.35
5.35
Vericel Corporation stock logo
VCEL
Vericel
N/A
5.01
4.58

Institutional Ownership

CompanyInstitutional Ownership
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
N/A
Howard Hughes Holdings Inc. stock logo
HHH
Howard Hughes
93.83%
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
77.70%
Vericel Corporation stock logo
VCEL
Vericel
N/A

Insider Ownership

CompanyInsider Ownership
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
4.30%
Howard Hughes Holdings Inc. stock logo
HHH
Howard Hughes
33.00%
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
3.78%
Vericel Corporation stock logo
VCEL
Vericel
5.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
39057.92 million55.43 millionOptionable
Howard Hughes Holdings Inc. stock logo
HHH
Howard Hughes
60850.39 million33.76 millionOptionable
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
180214.66 million206.55 millionOptionable
Vericel Corporation stock logo
VCEL
Vericel
30050.34 million47.73 millionOptionable

Recent News About These Companies

Vericel Corporation: Moving From Sell To Neutral

New MarketBeat Followers Over Time

Media Sentiment Over Time

Agios Pharmaceuticals stock logo

Agios Pharmaceuticals NASDAQ:AGIO

$39.26 -0.27 (-0.68%)
As of 10:44 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Howard Hughes stock logo

Howard Hughes NYSE:HHH

$70.39 -0.74 (-1.03%)
As of 10:44 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Howard Hughes Holdings Inc., together with its subsidiaries, operates as a real estate development company in the United States. It operates in four segments: Operating Assets; Master Planned Communities (MPCs); Seaport; and Strategic Developments. The Operating Assets segment consists of developed or acquired retail, office, and multi-family properties along with other retail investments. Its MPCs segment develops, sells, and leases residential and commercial land designated for long-term community development projects in and around Las Vegas, Nevada; Houston, Texas; and Phoenix, Arizona. The Seaport segment is involved in the landlord operations, managed businesses, and events and sponsorships services of its restaurant, retail, and entertain properties in Pier 17, New York City; Historic Area/Uplands; and Tin Building, as well as in 250 Water Street and in the Jean-Georges restaurants. The Strategic Development segment develops and redevelops residential condominiums and commercial properties. It serves homebuilders. Howard Hughes Holdings Inc. was founded in 2010 and is headquartered in The Woodlands, Texas.

Taysha Gene Therapies stock logo

Taysha Gene Therapies NASDAQ:TSHA

$2.64 +0.10 (+3.73%)
As of 10:44 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Vericel stock logo

Vericel NASDAQ:VCEL

$40.26 -0.97 (-2.35%)
As of 10:44 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.